Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biocon Receives DCGI Nod to Market Abraxane (India)

This article was originally published in PharmAsia News

Executive Summary

Biotech company Biocon Ltd. has received approval from the Drug Controller General of India to market Abraxane, its breast cancer drug. Biocon recently concluded a licensing agreement with U.S.-based Abraxis BioScience Inc. for the commercialization of Abraxane in India. Biocon has completed the required formalities to divest its enzymes business vertical to Novozymes South Asia Pvt Ltd, a wholly-owned subsidiary of Denmark-based Novozymes for Rs453.79 crore. Biocon will use the post tax proceeds of this divestment to strategically focus on its core bio-pharmaceuticals business as well as consider key acquisition opportunities to move up the value chain. (Click here for more - May Require Free Registration
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC065709

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel